JP2008156349A - Use of combination of at least one carotenoid with provitamin a activity and at least one carotenoid without provitamin a activity for treating ageing symptom - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a medicine for treating cutaneous symptoms of ageing, particularly degradation of the skin and/or of mucous membranes. <P>SOLUTION: The medicine comprises a combination of at least one carotenoid having provitamin A activity with at least a carotenoid without provitamin A activity. The carotenoid having provitamin A activity is preferably β-carotene and/or α-carotene, and at least a carotenoid without provitamin A activity is preferably zeaxanthin, lutein or lycopene. <P>COPYRIGHT: (C)2008,JPO&INPIT

Description

The invention relates to the use of a combination of at least one carotenoid having provitamin A activity and at least one carotenoid not having provitamin A activity in a composition or in the preparation of the composition, said combination Intended to treat signs of skin aging, in particular skin and / or mucosal degradation, by inhibiting collagenase activation and / or expression and increasing collagen synthesis. Concerning use.
The subject of the present invention is also a method for cosmetic treatment of the skin and / or mucous membrane.

Generally in mammals, particularly humans, the skin consists of two compartments: the epidermis, the compartment that contacts the exterior, and the dermis, the deep compartment that serves as a support for the epidermis.
The natural epidermis consists mainly of three types of cells: keratinocytes, melanocytes and Langerhans cells, which account for the majority. Each of these cell types contributes to the essential role that the skin plays in the body through its specific functions.

  The dermis provides a solid support for the epidermis. It is also a nutrient supply component of the epidermis. The dermis is mainly composed of fibroblasts and extracellular matrix, and the extracellular matrix itself is mainly composed of substances called collagen, elastin, and base substance, and these components are synthesized by fibroblasts. In addition, leukocytes, mast cells or tissue macrophages are also present. In addition, blood vessels and nerve fibers cross the dermis. In normal skin, i.e. skin without disease or wound healing, the fibroblasts are quiescent, i.e. non-proliferating, not very active from a metabolic point of view and do not move.

  Collagen fibers are a major factor in the robustness of the dermis. These fibers consist of fibrils that are tightly bound to each other, thus forming more than 10 different types of structures. The fastness of the dermis is mainly due to the entanglement of collagen fibers tightly bundled against each other in all directions. Collagen fibers also contribute to skin and / or mucosal elasticity, particularly tension.

Collagen fibers are constantly regenerated, but this regeneration decreases with age, causing the dermis thickness to decrease. This reduction in dermal thickness may also be due to pathological causes such as hypersecretion of corticoid hormones, certain diseases or vitamin deficiencies. It has also been recognized that exogenous factors such as ultraviolet light, tobacco or certain treatments (eg, glucocorticoids, vitamin D and derivatives thereof) also affect the skin and its collagen levels.
However, various factors contribute to collagen (collagenous fiber) degradation with all possible consequences for skin and / or mucosal structure and / or firmness.

Collagen fibers are very resistant but sensitive to a certain enzyme called collagenase. Collagen fiber degradation is responsible for the appearance of sagging and wrinkled skin, especially those who prefer a smooth and firm skin appearance have always tried to resist them.
Collagenase is itself a member of the proteolytic enzyme (endoprotease) family, with three active cysteine residues and a zinc atom coordinated to one methionine, and at neutral pH in the basal layer and cells. It forms part of an enzyme family called metalloproteinases (MMPs) that degrade macromolecular components (collagen, elastin, etc.) of the outer matrix. These enzymes are very widely distributed in the biological kingdom and are present during normal physiological conditions, such as organ growth and tissue regeneration, but only weakly expressed.
However, their overexpression and their activation are involved in many processes, including pathological processes, including matrix destruction and remodeling. This can lead to an inability to regulate the absorption of the extracellular matrix and, conversely, a fibrotic condition.

The metalloproteinase family consists of several well-defined groups based on substrate specificity and structural similarity (see Woessner JF, Fasb Journal, Vol. 5, 1991, pages 2145). These groups include collagenases for degradation of fibrillar collagen (MMP-1 or stromal collagenase, MMP-8 or neutrophil collagenase, MMP-13 or collagenase 3), type IV collagen or any form of denaturation. Gelatinase that degrades collagen [MMP-2, ie, gelatinase A (72 kDa), MMP-9, ie, gelatinase B (92 kDa)], and a wide spectrum of activity in extracellular matrix proteins such as glycoproteins (fibronectin, laminin), proteoglycans, etc. Examples include stromeline (MMP-3) or membrane-type metalloproteinases that have an effect.
Exposure to ultraviolet light, particularly UVA and / or UVB, over a long period of time has the effect of stimulating the expression of collagenase, particularly MMP-1. This is one element of light-induced skin aging.

  Furthermore, the main change for the dermis during menopause is a decrease in collagen levels and dermis thickness. This is the cause of reduced skin and / or mucosal thickness in menopausal women. Thus, women experience “dry skin”, a feeling of tension in the skin, wrinkles on the surface, and wrinkles becoming visible. The skin becomes rough when touched. Finally, a decrease in skin flexibility is also observed.

  Thus, after reading the above description, the importance of collagen in tissue structures, especially skin and / or mucous membranes, and the ability to resist collagen degradation and thus age or light induced To understand the importance of controlling the signs of aging and the consequences thereof, for example, reducing the thickness of the dermis that causes the appearance of sagging, swelling and wrinkled skin, and / or the degradation of collagen fibers it can.

Signs of signs of skin aging include wrinkles and wrinkles, withered skin, soft skin, reduced thickness skin, dull skin and non-shine skin, Exposure to ultraviolet light, which may result in a reduction in dermis thickness as well as any changes in skin appearance with age, regardless of age and / or light-induced, such as loss of elasticity and / or tension. It is understood to mean any internal change of the skin that does not result in a systematic altered appearance, such as any internal damage to the skin after it has been applied, especially the collagen fibers.
US Pat. No. 5,895,652 JP 2000-229827 A JP-A-11-35444 JP-A-8-225428 JP 2000-511923 A International Publication No. 99/43329 Pamphlet JP 2000-86505 A International Publication No. 98/55075 Pamphlet JP 2000-86489 A Japanese Patent Laid-Open No. 11-246332 JP-A-11-246333 Japanese Patent Laid-Open No. 11-246328 WO99 / 32078 pamphlet

Thus, one of the objects of the present invention is to provide a general indication of signs of skin aging, particularly a reduction in dermal thickness and / or collagen fiber degradation, regardless of age or light-induced, in mammals, particularly humans. It is possible to obtain a prophylactically or curatively treatable product with a stimulating effect on the synthesis of and / or an inhibitory effect on collagenase, if possible without any noticeable side effects.
Surprisingly, Applicants have obtained a combination of at least one carotenoid having provitamin A activity and at least one carotenoid having no provitamin A activity, regardless of age or light-induced. Signs of skin aging, especially the reduction of dermal thickness and / or collagen fiber degradation, can be treated prophylactically and / or curatively by stimulating effects on collagen synthesis and / or inhibiting effects on collagenase. I found out.

One of the salient properties of the combination of the present invention is that it has a higher proportion of effects than is reasonably expected from a simple sum of the effects obtained separately by each of these components. .
One advantage of this property is that each product can be used in the compositions of the present invention in an amount that is less than typical acceptable use.
To the best of Applicant's knowledge, a combination of at least one carotenoid having provitamin A activity and at least one carotenoid having no provitamin A activity stimulates collagen synthesis, produces collagenase expression and Nothing has been described yet about the inhibition of activation.

Accordingly, the first subject of the invention is in the composition or in the preparation of a composition of a combination of at least one carotenoid with provitamin A activity and at least one carotenoid without provitamin A activity. Use wherein the combination or the composition is intended for the treatment of signs of skin aging.
The second subject of the invention is also the use of a combination of at least one carotenoid with provitamin A activity and at least one carotenoid without provitamin A activity in a composition or in the preparation of a composition. Wherein the combination or the composition is intended to resist collagen degradation.
Furthermore, a third subject of the invention is the use of a combination of at least one carotenoid with provitamin A activity and at least one carotenoid without provitamin A activity in a composition or in the preparation of a composition Wherein the combination or composition is intended to inhibit the expression of proteases in the extracellular matrix, in particular metalloproteinases, and even metalloproteinase type 1.

Furthermore, a fourth subject of the present invention is the use of a combination of at least one carotenoid with provitamin A activity and at least one carotenoid without provitamin A activity in a composition or in the preparation of a composition The combination or the composition is intended for the treatment of skin conditions associated with aging, in particular at the menopause.
Furthermore, a fifth subject of the invention is the use of a combination of at least one carotenoid with provitamin A activity and at least one carotenoid without provitamin A activity in a composition or in the preparation of a composition Wherein the combination or the composition is intended to resist wrinkles and wrinkles.
Further, the sixth subject of the present invention is the use of a combination of at least one carotenoid with provitamin A activity and at least one carotenoid without provitamin A activity in a composition or in the preparation of a composition Wherein the combination or the composition is intended to resist weakened skin.

Furthermore, a seventh subject of the present invention is the use of a combination of at least one carotenoid with provitamin A activity and at least one carotenoid without provitamin A activity in a composition or in the preparation of a composition Wherein the combination or composition is intended to resist sagging skin.
Furthermore, an eighth subject of the present invention is the use of a combination of at least one carotenoid with provitamin A activity and at least one carotenoid without provitamin A activity in a composition or in the preparation of a composition Wherein the combination or composition is intended to resist reduced thickness skin.

Furthermore, a ninth subject of the invention is the use of a combination of at least one carotenoid with provitamin A activity and at least one carotenoid without provitamin A activity in a composition or in the preparation of a composition In which the combination or the composition is intended to resist dull or non-shiny skin.
Furthermore, a tenth subject of the present invention is the use of a combination of at least one carotenoid having provitamin A activity and at least one carotenoid not having provitamin A activity in a composition or in the preparation of a composition. Wherein the combination or the composition is intended to resist loss of skin elasticity and / or tension.
Whatever the use contemplated in the present invention, the target condition can be treated prophylactically and / or curatively.
It is clear that the present invention is generally directed to mammals, particularly humans.

In the present invention, the carotenoid having provitamin A activity may be a mixture of carotenoids having provitamin A activity. This mixture can be in any proportion. Examples of carotenoids having provitamin A activity include β-carotene and α-carotene. In the present invention, β-carotene is preferably used.
In the present invention, the carotenoid having no provitamin A activity may be a mixture of carotenoids having no provitamin A activity. This mixture can be in any proportion. Examples of carotenoids that do not have provitamin A activity include zeaxanthin, lutein, and lycopene.
In the present invention, lycopene is preferably used.

Lycopene is a natural pigment found in ripe fruits, especially tomatoes. It belongs to the carotenoid family and its structure is similar to that of β-carotene. The role of lycopene in fruit ripening is known in the prior art.
Lycopene is an anti-free radical agent (Japanese Patent Application Publication No. 8-283136), a composition intended for the treatment of acne and / or hair due to its activity in 5-reductase (Japanese Patent No. 2940964), Or it is used for the composition (WO 97/47278) having santan activity because of its role in melanin synthesis.
Lycopene may be in the cis or trans chemical form.

The carotenoids with or without provitamin A activity used in the present invention may be of natural or synthetic origin.
The expression derived from nature is understood to mean a carotenoid in solution or in a pure state, obtained from a natural component, of any concentration in solution.
In a preferred embodiment of the invention, a lycopene rich extract, for example a tomato extract, is used.
The expression derived from synthesis is understood to mean a carotenoid in solution or in a pure state, obtained by chemical synthesis, in any concentration in solution.

If the carotenoid is naturally derived, it may be derived from whole plant grown in vivo or from plant material derived from in vitro crops.
The expression in-vivo cultivation is understood to mean any conventional type of cultivation, i.e. cultivation in soil, outdoors or greenhouse, or soil-free cultivation.
The expression in vitro cultivation is understood to mean all techniques known to the person skilled in the art that can artificially obtain plants or plant parts. The selective pressure imposed by physicochemical conditions during the growth of plant cells in vitro makes it possible to obtain standardized plant materials that are available year round, unlike plants grown in vivo.
In the present invention, plants obtained from in vivo cultivation are preferably used.

Any extraction method known to those skilled in the art can be used to prepare the carotenoids used in the present invention.
The carotenoid may be in the form of an alcohol, especially an ethanol solution.
Carotenoids may also be in the form of lipids (oils) or lipoalcoholic solutions.

In the present invention, for example, a lycopene-rich tomato consisting of an oleoresin extract (fatty phase) containing 6% pure lycopene, prepared from Metaphar and marketed under the name LycOMato® Carotenoids that do not have provitamin A activity are used in the form of extracts.
Also in the present invention, any preparation containing lycopene with the purpose of improving the bioavailability of lycopene, and / or any novel for the production and / or formulation and / or encapsulation of lycopene A method can also be used.

Of course, the amount of carotenoids with provitamin A activity that can be used in the present invention depends on the desired effect and can therefore vary to a large extent.
As a guideline, in the composition of the present invention, the carotenoid having pure vitamin A activity is in an amount of ^10-12 % to 20%, preferably the total weight of the composition, relative to the total weight of the composition. The amount is 10 ⁻¹⁰ % to 10%.
Of course, the amount of carotenoids without provitamin A activity that can be used in the present invention depends on the desired effect and can therefore vary to a large extent.
As a guide, carotenoids that do not have pure provitamin A activity in the compositions of the present invention are in an amount of ^10-12 % to 20%, preferably of the composition, relative to the total weight of the composition. The amount is 10 ⁻¹⁰ % to 10% with respect to the total weight.
Of course, the person skilled in the art, when using carotenoids with provitamin A activity and / or carotenoids without provitamin A activity as solution forms, for example plant extracts, the final amount of carotenoid in the composition It can be seen how to adjust the amount of solution used in the composition so that is the above-mentioned usable amount.

The composition of the present invention can be in any conceivable galenos form suitable for both topical application to the skin and / or mucous membranes and / or hair and administration by oral route.
Preferably, the compositions of the present invention are intended to be administered by the oral route.

The composition of the present invention may be a cosmetic or dermatological composition. Preferably in the present invention, the composition is a cosmetic composition. A composition is a cosmetic composition if it is intended to improve the general skin appearance of the individual who uses it.
Most preferably, the composition of the present invention is a cosmetic composition intended to be administered by the oral route.
When administered by the oral route, the compositions of the invention are provided in any suitable form, preferably as an oral solution, syrup, tablet, dragee, hard gelatin capsule or soft gelatin capsule, or nutritional food or supplement. Can do.
The composition may further contain at least one suitable excipient suitable for oral administration.

  When administered by topical application to the skin, hair and / or body hair and / or mucous membrane, the composition of the present invention comprises a cosmetically acceptable carrier, ie a carrier compatible with the skin, mucous membrane, nails and hair. It is clear that it contains and any galenos form normally used for topical application, especially aqueous, aqueous-alcohol or oily solutions, oil-in-water or water-in-oil or multiphase emulsions, aqueous or oily gels, anhydrous Aqueous phase using a liquid, pasty or solid product, polymer nanoparticles, eg nanospheres and nanocapsules, more preferably spheres which may be ionic and / or nonionic lipid vesicles It can be provided as a dispersion of oil.

The composition may be more or less fluid and may have the appearance of a white or colored cream, ointment, milk, lotion, serum, paste, foam. Alternatively, it may be applied to the skin in the form of an aerosol. Further, it can be provided in a solid form, for example, a stick form. Furthermore, it can be used as a treatment product, a cleansing product, a makeup product, or a simple deodorizing product.
In a known manner, the compositions according to the invention can also be applied to adjuvants customary in the cosmetic and dermatological field, for example hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active ingredients, antiseptics. An agent, an antioxidant, a solvent, a fragrance, a filler, a screen agent, a pigment, a chelating agent, an odor absorber, and a coloring substance may be further contained. The amounts of these various adjuvants are those conventionally used in the field under consideration, for example 0.01% to 20% relative to the total weight of the composition. Depending on their nature, these adjuvants can be incorporated into the fatty phase, aqueous phase, lipid vesicles and / or nanoparticles.

  When the composition of the present invention is an emulsion, the proportion of the fatty phase is in the range of 5 to 80% by weight, preferably 5 to 50% by weight, based on the total weight of the composition. The oils, emulsifiers and coemulsifiers used in the composition in the form of an emulsion are selected from those conventionally used in the field considered. The emulsifier and coemulsifier are present in the composition in a proportion ranging from 0.3 to 30% by weight, preferably from 0.5 to 20% by weight, relative to the total weight of the composition.

Examples of the oil that can be used in the present invention include mineral oil, plant-derived oil (apricot oil, sunflower oil), animal-derived oil, synthetic oil, silicone oil, and fluorinated oil (perfluoropolyether). . As the fat, fatty alcohol (cetyl alcohol), fatty acid, wax (beeswax) can also be used.
Examples of emulsifiers and coemulsifiers that can be used in the present invention include polyethylene glycol and fatty acid esters such as PEG-40 stearate, PEG-100 stearate, polyol and fatty acid esters such as glyceryl stearate and sorbitan tristearate. Can be mentioned.
Hydrophilic gelling agents include, in particular, carboxyvinyl polymers (carbomers), acrylic copolymers such as acrylate / alkyl acrylate copolymers, polyacrylamides, polysaccharides, natural gums and clays. Examples of lipophilic gelling agents include modified clays such as bentones, metal salts of fatty acids, hydrophobic silica, and polyethylene.

The composition may contain other hydrophilic active agents such as proteins or protein hydrolysates, amino acids, polyols, ureas, allantoins, sugars and sugar derivatives, plant extracts and hydroxy acids.
As lipophilic active agents, retinol (vitamin A) and its derivatives, tocopherol (vitamin E) and its derivatives, essential fatty acids, ceramides, essential oils, salicylic acid and its derivatives, or vitamins B1, B6 and / or B12 are used. can do.
Vitamin C (or ascorbic acid) and its derivatives (esters, salts, etc.) can also be used in the composition of the present invention.
Also, a plant extract rich in isoflavonoids, such as a soy extract (Glycina max) available from the company Archer Daniels Midland under the name Novasoy®. It can also be added.

Preferred compositions of the present invention are enriched in isoflavonoids in a combination of at least one carotenoid having provitamin A activity and at least one carotenoid having no provitamin A activity, with other ingredients. Contains plant extract, vitamin C and α-tocopherol.
Even more preferably, the composition of the present invention is a combination of β-carotene and lycopene, a soy extract (Novasoy® from Archer-Daniels-Midland), vitamin C and Contains α-tocopherol acetate.

Also included in the composition of the present invention:
-Trace elements;
-Plant hormones;
-Calcium antagonists such as verapamil and diltiazem;
An OH group scavenger, such as dimethyl sulfoxide;
-Chlorine channel opener;
-Plant extracts, such as those of the family Iridaceae, Rosaceae or Rosmarinus;
-Microbial extracts, especially including bacterial extracts, such as non-photosynthetic filamentous fungi;
A compound selected from can also be used.

  Furthermore, the above list is described in other compounds such as potassium channel openers such as diazoxide and minoxidil, spiroxazone, phospholipids such as lecithin, linoleic acid and linolenic acid, salicylic acid and French Patent No. 2581542. Derivatives thereof, for example salicylic acid derivatives carrying alkanoyl groups having 2 to 12 carbon atoms in the 5-position of the benzene ring, hydroxycarboxylic acids or ketocarboxylic acids and their esters, lactones and their corresponding salts, anthralins, carotenoids, Eicosatetraenoic acid and eicosatrienoic acid or their esters and amides, vitamin D and its derivatives can also be added.

In the context of the present invention, other active agents specifically intended for the prevention and / or treatment of skin conditions may be added to the composition of the present invention. These activators include, for example:
-Agents that modulate skin differentiation and / or proliferation and / or pigmentation, such as retinoic acid and its isomers, retinol and its esters, vitamin D and its derivatives, estrogens such as estradiol, kojic acid or hydroquinone;
-Antibacterial agents such as clindamycin phosphate, erythromycin or tetracycline class antibiotics;
-Agents that modulate the attachment of bacteria to the skin and / or mucous membranes, such as honey, in particular acacia honey and certain sugar derivatives;
-Anthelmintic agents, in particular metronidazole, crotamiton and pyrethrinoids;
-Antifungal agents, in particular compounds belonging to the imidazole class, such as econazole, ketoconazole or miconazole or their salts, polyene compounds such as amphotericin B, compounds of the allylamine family, such as terbinafine or octopirox;
An antiviral agent, such as acyclovir;
-Steroidal anti-inflammatory agents such as hydrocortisone, betamethasone valerate or clobetasol propionate, or non-steroidal anti-inflammatory agents such as ibuprofen and its salts, diclofenac and its salts, acetylsalicylic acid, acetaminophen or glycyrrhetinic acid;
-Anesthetics such as lidocaine hydrochloride and its derivatives;
An antidiarrheal, such as tenaldine, trimeprazine or cyproheptadine;
Keratolytic agents such as α- and β-hydroxycarboxylic acids or β-ketocarboxylic acids, their salts, amides or esters, in particular hydroxy acids such as glycolic acid, lactic acid, salicylic acid, citric acid, and generally fruit acid, and 5 -n-octanoylsalicylic acid;
An anti-free radical agent such as superoxide dismutase, certain metal chelators, or ascorbic acid and its esters;
An antiseborrheic agent, such as progesterone;
-Anti-dandruff agents, such as octopirox or zinc pyrithione;
-Anti-acne agents, such as retinoic acid or benzoyl peroxide;
-Substance P, CGRP or bradykinin antagonist or NO synthase inhibitor, or sodium channel inhibitor, active in the treatment of sensitive skin, described as having an anti-irritant effect, especially on irritating compounds that may be present in the composition Substances such as compounds,
Can be mentioned.

Moisturizers such as polyols (eg glycerin), vitamins (eg D-panthenol), anti-inflammatory agents, soothing agents (allantoin, cornflower water), UVA- and UVB screening agents, matting agents (eg Partly cross-linked polydimethylorganosiloxane sold by Shin-Etsu under the name KSG®) and mixtures thereof can be used in particular as activators.
Also, anti-wrinkle active agents, in particular toning products such as plant proteins and their hydrolysates, in particular soy protein extract sold under the name Eleseryl® from LSN, Alternatively, an oat derivative sold under the name Reductine® from Silab may be added.

Since the skin consists of many other components besides collagen and fibroblasts, when using the combination of the present invention, at the same time it promotes the synthesis of these other components such as lipids and / or keratinocytes, etc. It is advantageous to promote the growth of other cellular components.
Thus, the subject of the present invention is a combination of at least one carotenoid having provitamin A activity and at least one carotenoid having no provitamin A activity in a cosmetically acceptable medium, In a composition comprising at least one other product that stimulates synthesis and / or proliferation of keratinocytes.
In this composition, the carotenoid having provitamin A activity and the carotenoid having no provitamin A activity are those described above in the present specification.
The composition can be intended for use in the cosmetic or dermatological field, preferably in the cosmetic field.

Products that stimulate lipid synthesis include plant hormones such as auxin, or plant derived compounds such as cinnamic acid, and products that stimulate the growth of keratinocytes include plant derived compounds such as phloroglucinol. be able to.
Thus, the composition of the invention comprises a combination of the invention, cinnamic acid or a derivative thereof and / or a plant hormone, in particular indoleacetic acid (IAA), 4-chloroindole-3-acetic acid (4-CI-IAA), Phenylacetic acid (PAA), indole-3-butyric acid (IBA), 2,4-dichlorophenoxyacetic acid (2,4-D), α-naphthaleneacetic acid (α-NAA), β-naphthoxyacetic acid, indoleethanol, indoleacetaldehyde And auxin selected from indoleacetonitrile and / or plant compounds such as phloroglucinol.

  The subject of the invention is also a combination of at least one carotenoid with provitamin A activity and at least one carotenoid without provitamin A activity, and at least one which stimulates lipid synthesis and / or keratinocyte proliferation. Use of other products of the species in the composition or in the preparation of the composition, wherein the combination or the composition treats signs of skin aging prophylactically and / or curatively and collagen degradation Inhibiting the expression of proteases in the extracellular matrix, inhibiting the expression of metalloproteinases, particularly metalloproteinase type 1, treating the skin conditions associated with menopause, resisting wrinkles and wrinkles, Resists skin sagging, resists skin thickness reduction, resists skin dullness and / or loss of skin glow, Against the loss of elasticity and / or tension, in use intended for combating internal damage of the skin after exposure to ultraviolet light.

The subject of the invention also stimulates the synthesis of collagen and / or resists skin conditions associated with aging and / or menopause and / or resists dermal thickness reduction and / or sagging and In a cosmetic treatment method intended to resist skin with a wrinkled appearance, at least one carotenoid having provitamin A activity and at least one carotenoid having no provitamin A activity A cosmetic composition containing the combination is applied to the skin, head hair and / or body hair and / or mucous membrane and ingested.
The cosmetic treatment method of the present invention is carried out in particular by applying these compositions according to the usual technique using the cosmetic compositions described above.
For example, creams, gels, serums, lotions, milk, shampoos, or application of the composition for protection against sunlight to the skin or hair or body hair, or application of dentifrices to gums, preferably oral solutions, syrups, Oral administration of tablets, hard gelatin capsules, soft gelatin capsules or nutritional foods or nutritional supplements.

The following examples and compositions are illustrative of the invention and are not limiting. The proportions shown in the composition are percent by weight.
Composition 1-Soft gelatin capsule:
Excipient:
Soybean oil 40mg
Wheat germ oil 85mg
Soy lecithin 25mg
vitamin:
Natural tocopherol 3mg
Vitamin C 50mg
component:
Lycopene 6mg
β-carotene 10mg

Composition 2: Cream for care (oil-in-water emulsion)
6% lycopene [Lycomat (up to 0.001%
Registered trademark)]
β-Carotene 0.01%
Glyceryl stearate 2.00%
Polysorbate 60 [Sold from ICI 1.00%
Tween 60 (registered trademark)]
Stearic acid 1.40%
Triethanolamine 0.70%
Carbomer 0.40%
Shea butter liquid fraction 12.00%
Perhydrosqualene 12.00%
Antioxidant 0.05%
Fragrance 0.50%
Preservative 0.30%
The amount to make the whole water 100.00%

Composition 3: Facial care gel 6% lycopene (RIKOMAT®) 0.001%
β-Carotene 0.01%
Hydroxypropylcellulose [Haki 1.00%
Klucel H (registered trademark) sold by Hercules]
Antioxidant 0.05%
Isopropanol 40.00%
Preservative 0.30%
The amount to make the whole water 100.00%

Composition 4: Cream for care (oil-in-water emulsion)
6% lycopene (RIKOMAT®) 0.001%
β-Carotene 0.01%
Glyceryl stearate 2.00%
Polysorbate 60 (sold by ICI 1.00%
Tween 60 (registered trademark)]
Stearic acid 1.40%
Glycyrrhetinic acid 2.00%
Triethanolamine 0.70%
Carbomer 0.40%
Shea butter liquid fraction 12.00%
Sunflower oil 10.00%
Antioxidant 0.05%
Fragrance 0.50%
Preservative 0.30%
The amount to make the whole water 100.00%

Claims (30)

  A medicament for treating signs of skin aging comprising a combination of at least one carotenoid having provitamin A activity and at least one carotenoid having no provitamin A activity.   An agent for resisting collagen degradation, comprising a combination of at least one carotenoid having provitamin A activity and at least one carotenoid having no provitamin A activity.   An agent for inhibiting the expression of proteases in the extracellular matrix, comprising a combination of at least one carotenoid having provitamin A activity and at least one carotenoid having no provitamin A activity.   The drug according to claim 3, which is intended to inhibit the expression of metalloproteinase.   The drug according to claim 3 or 4, which is intended to inhibit the expression of metalloproteinase type 1.   An agent for the treatment of menopausal skin conditions, comprising a combination of at least one carotenoid having provitamin A activity and at least one carotenoid having no provitamin A activity.   An agent for combating wrinkles and wrinkles comprising a combination of at least one carotenoid having provitamin A activity and at least one carotenoid having no provitamin A activity.   An agent for combating weakened skin, comprising a combination of at least one carotenoid having provitamin A activity and at least one carotenoid having no provitamin A activity.   An agent for combating sagging skin, comprising a combination of at least one carotenoid having provitamin A activity and at least one carotenoid having no provitamin A activity.   An agent for resisting skin thickness reduction, comprising a combination of at least one carotenoid having provitamin A activity and at least one carotenoid having no provitamin A activity.   An agent for combating dull skin and / or non-shine skin, comprising a combination of at least one carotenoid having provitamin A activity and at least one carotenoid having no provitamin A activity.   An agent for combating skin elasticity and / or loss of tension, comprising a combination of at least one carotenoid having provitamin A activity and at least one carotenoid having no provitamin A activity.   An agent for resisting internal skin damage after exposure to ultraviolet radiation, comprising a combination of at least one carotenoid having provitamin A activity and at least one carotenoid having no provitamin A activity.   14. The drug according to any one of claims 1 to 13, wherein the carotenoid having provitamin A activity is selected from β-carotene or α-carotene, or a mixture of the two.   The drug according to claim 14, wherein the carotenoid having provitamin A activity is β-carotene.   The drug according to any one of claims 1 to 15, wherein the carotenoid having no provitamin A activity is selected from zeaxanthin, lutein or lycopene.   15. The drug according to claim 14, wherein the carotenoid having no provitamin A activity is lycopene. 18. A carotenoid with pure vitamin A activity is in an amount of ^10-12 % to 20% relative to the total weight of the composition. Drug. 19. The carotenoid with pure vitamin A activity is in an amount of ^10-10 % to 10% with respect to the total weight of the composition. Drug. 20. A carotenoid having no pure vitamin A activity is in an amount of ^10-12 % to 20% relative to the total weight of the composition. The drug described. 21. The carotenoid having no pure vitamin A activity is in an amount of ^10-10 % to 10% with respect to the total weight of the composition. The drug described.   The medicament according to any one of claims 1 to 21, wherein the composition is intended to be administered by oral route.   23. The composition according to claim 1, wherein the composition is provided in the form of an oral solution, syrup, tablet, sugar-coated tablet, hard gelatin capsule, or soft gelatin capsule, or nutritional food or nutritional supplement. Item 1. The drug according to item 1.   A combination of at least one carotenoid having provitamin A activity and at least one carotenoid having no provitamin A activity and at least one other product that stimulates lipid synthesis and / or keratinocyte proliferation A cosmetic composition containing   25. The composition of claim 24, wherein the carotenoid having provitamin A activity is that of any one of claims 14, 15, 18 or 19.   26. The composition according to claim 24 or 25, wherein the carotenoid having no provitamin A activity is that according to any one of claims 16, 17, 20 or 21.   27. The product according to any one of claims 24 to 26, wherein the product that stimulates lipid synthesis is selected from plant hormones such as auxin, or plant-derived compounds such as cinnamic acid or derivatives thereof. Composition.   Auxin is indoleacetic acid (IAA), 4-chloroindole-3-acetic acid (4-CI-IAA), phenylacetic acid (PAA), indole-3-butyric acid (IBA), 2,4-dichlorophenoxyacetic acid (2, 28. The method according to any one of claims 24 to 27, characterized in that it is selected from 4-D), α-naphthalene acetic acid (α-NAA), β-naphthoxyacetic acid, indole ethanol, indole acetaldehyde and indole acetonitrile. Composition.   29. A composition according to any one of claims 24 to 28, wherein the product that stimulates the growth of keratinocytes is phloroglucinol.   A combination of at least one carotenoid with provitamin A activity and at least one carotenoid without provitamin A activity, and at least one other product that stimulates lipid synthesis and / or keratinocyte proliferation In the composition or in the preparation of the composition, wherein the combination or the composition treats signs of skin aging prophylactically and / or curatively, resists collagen degradation and is extracellular Inhibits the expression of proteases in the matrix, inhibits the expression of metalloproteinases, particularly metalloproteinase type 1, treats skin conditions associated with menopause, resists wrinkles and wrinkles, resists skin deterioration, sagging skin Resists skin thickness reduction, resists skin dullness and / or loss of skin radiance, skin elasticity and / or tightness. Against the loss, use is intended to be against the internal damage of the skin after exposure to ultraviolet light.